UCB (UCB.BR) Financials
UCB.BR Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 15.5 billion | 6.6 billion |
| 2023-06-30 | 15.4 billion | 6.3 billion |
| 2023-03-31 | ? | ? |
| 2022-12-31 | 15.9 billion | 6.8 billion |
UCB.BR Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | 311.0 million | -629.0 million |
| 2023-06-30 | -10.0 million | -18.0 million |
| 2023-03-31 | ? | ? |
| 2022-12-31 | 480.0 million | -393.0 million |
UCB.BR Net Income
| Date | Net Income |
|---|---|
| 2023-12-31 | 32.0 million |
| 2023-06-30 | 311.0 million |
| 2023-03-31 | 155.5 million |
| 2022-12-31 | 21.0 million |
UCB.BR Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 969.0 million | - | 161.0 million |
| 2023-06-30 | 457.0 million | - | 157.0 million |
| 2023-03-31 | - | - | - |
| 2022-12-31 | 1.1 billion | - | 140.0 million |
UCB.BR Shares Outstanding
UCB.BR Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 158.0 million | 871.0 million | - | - |
| 2023-06-30 | 158.0 million | 759.0 million | 104.0 million | 753.0 million |
| 2023-03-31 | - | - | - | - |
| 2022-12-31 | 197.0 million | 872.0 million | - | - |
UCB.BR Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 2.7 billion | 1.0 billion |
| 2023-06-30 | 2.6 billion | 901.0 million |
| 2023-03-31 | - | - |
| 2022-12-31 | 2.6 billion | 925.0 million |
UCB.BR
Price: €123
Dividend Yield: 0.01%
Forward Dividend Yield: 1.11%
Payout Ratio: 77.27%
Dividend Per Share: 1.36 EUR
Earnings Per Share: 1.76 EUR
P/E Ratio: 50.67
Exchange: BRU
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 21.7 billion
Average Dividend Frequency: 1
Years Paying Dividends: 25
DGR3: 2.33%